Risk Models to Predict Chronic Kidney Disease and Its Progression: A Systematic Review
Background:
Chronic kidney disease (CKD) is common, and associated with increased risk of cardiovascular disease and end-stage renal disease, which are potentially preventable through early identification and treatment of individuals at risk. Although risk factors for occurrence and progression of CKD have been identified, their utility for CKD risk stratification through prediction models remains unclear. We critically assessed risk models to predict CKD and its progression, and evaluated their suitability for clinical use.
Methods and Findings:
We systematically searched MEDLINE and Embase (1 January 1980 to 20 June 2012). Dual review was conducted to identify studies that reported on the development, validation, or impact assessment of a model constructed to predict the occurrence/presence of CKD or progression to advanced stages. Data were extracted on study characteristics, risk predictors, discrimination, calibration, and reclassification performance of models, as well as validation and impact analyses. We included 26 publications reporting on 30 CKD occurrence prediction risk scores and 17 CKD progression prediction risk scores. The vast majority of CKD risk models had acceptable-to-good discriminatory performance (area under the receiver operating characteristic curve>0.70) in the derivation sample. Calibration was less commonly assessed, but overall was found to be acceptable. Only eight CKD occurrence and five CKD progression risk models have been externally validated, displaying modest-to-acceptable discrimination. Whether novel biomarkers of CKD (circulatory or genetic) can improve prediction largely remains unclear, and impact studies of CKD prediction models have not yet been conducted. Limitations of risk models include the lack of ethnic diversity in derivation samples, and the scarcity of validation studies. The review is limited by the lack of an agreed-on system for rating prediction models, and the difficulty of assessing publication bias.
Conclusions:
The development and clinical application of renal risk scores is in its infancy; however, the discriminatory performance of existing tools is acceptable. The effect of using these models in practice is still to be explored.
Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Risk Models to Predict Chronic Kidney Disease and Its Progression: A Systematic Review. PLoS Med 9(11): e32767. doi:10.1371/journal.pmed.1001344
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001344
Souhrn
Background:
Chronic kidney disease (CKD) is common, and associated with increased risk of cardiovascular disease and end-stage renal disease, which are potentially preventable through early identification and treatment of individuals at risk. Although risk factors for occurrence and progression of CKD have been identified, their utility for CKD risk stratification through prediction models remains unclear. We critically assessed risk models to predict CKD and its progression, and evaluated their suitability for clinical use.
Methods and Findings:
We systematically searched MEDLINE and Embase (1 January 1980 to 20 June 2012). Dual review was conducted to identify studies that reported on the development, validation, or impact assessment of a model constructed to predict the occurrence/presence of CKD or progression to advanced stages. Data were extracted on study characteristics, risk predictors, discrimination, calibration, and reclassification performance of models, as well as validation and impact analyses. We included 26 publications reporting on 30 CKD occurrence prediction risk scores and 17 CKD progression prediction risk scores. The vast majority of CKD risk models had acceptable-to-good discriminatory performance (area under the receiver operating characteristic curve>0.70) in the derivation sample. Calibration was less commonly assessed, but overall was found to be acceptable. Only eight CKD occurrence and five CKD progression risk models have been externally validated, displaying modest-to-acceptable discrimination. Whether novel biomarkers of CKD (circulatory or genetic) can improve prediction largely remains unclear, and impact studies of CKD prediction models have not yet been conducted. Limitations of risk models include the lack of ethnic diversity in derivation samples, and the scarcity of validation studies. The review is limited by the lack of an agreed-on system for rating prediction models, and the difficulty of assessing publication bias.
Conclusions:
The development and clinical application of renal risk scores is in its infancy; however, the discriminatory performance of existing tools is acceptable. The effect of using these models in practice is still to be explored.
Please see later in the article for the Editors' Summary
Zdroje
1. CoreshJ, SelvinE, StevensLA, ManziJ, KusekJW, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047.
2. ZhangQL, RothenbacherD (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8: 117.
3. KhanS, AmediaCAJr (2008) Economic burden of chronic kidney disease. J Eval Clin Pract 14: 422–434.
4. FinkHA, IshaniA, TaylorBC, GreerNL, MacDonaldR, et al. (2012) Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 156: 570–581.
5. UhligK, LeveyAS (2012) Developing guidelines for chronic kidney disease: we should include all of the outcomes. Ann Intern Med 156: 599–601.
6. LeveyAS, CoreshJ (2012) Chronic kidney disease. Lancet 379: 165–180.
7. Whaley-ConnellA, ShlipakMG, InkerLA, Kurella TamuraM, BombackAS, et al. (2012) Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med 125: 661–669.
8. AkbariA, GrimshawJ, StaceyD, HoggW, RamsayT, et al. (2012) Change in appropriate referrals to nephrologists after the introduction of automatic reporting of the estimated glomerular filtration rate. CMAJ 184: E269–E276.
9. MoonsKG, KengneAP, WoodwardM, RoystonP, VergouweY, et al. (2012) Risk prediction models: I. development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 98: 683–690.
10. MoonsKG, KengneAP, GrobbeeDE, RoystonP, VergouweY, et al. (2012) Risk prediction models: II. external validation, model updating, and impact assessment. Heart 98: 691–698.
11. ReillyBM, EvansAT (2006) Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med 144: 201–209.
12. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1–S266.
13. National Collaborating Centre for Chronic Conditions (2008) Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. NICE clinical guideline 73. London: National Institute for Health and Clinical Excellence. Available: http://www.nice.org.uk/nicemedia/live/12069/42117/42117.pdf. Accessed 10 October 2012.
14. International Society of Nephrology (2012) Clinical practice guidelines. Available: http://www.theisn.org/isn-information/clinical-practice-guidelines/itemid-482. Accessed 5 May 2012.
15. HeemannU, AbramowiczD, SpasovskiG, VanholderR (2011) Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant 26: 2099–2106.
16. Canadian Society of Nephrology (2008) Guideline document library. Available: http://www.csnscn.ca/site/c.lnKKKOOvHqE/b.8079309/k.799F/Guideline_Document_Library.htm. Accessed 5 May 2012.
17. Kidney Disease: Improving Global Outcomes (2009) Clinical practice guidelines. Available: http://www.kdigo.org/clinical_practice_guidelines/index.php. Accessed 5 May 2012.
18. Japanese Society for Dialysis Therapy (2008) Guidelines. Available: http://www.jsdt.or.jp/guideline.html. Accessed 10 October 2012.
19. ImaiE, YasudaY, MakinoH (2011) Japan Association of Chronic Kidney Disease Initiatives (J-CKDI). Japan Med Assoc J 54: 403–405.
20. Taiwan Society of Nephrology (2012) History and mission. Available: http://www.tsn.org.tw/englishVersion/History.aspx. Accessed 5 May 2012.
21. BangH, VupputuriS, ShohamDA, KlemmerPJ, FalkRJ, et al. (2007) SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med 167: 374–381.
22. BlechI, KatzenellenbogenM, KatzenellenbogenA, WainsteinJ, RubinsteinA, et al. (2011) Predicting diabetic nephropathy using a multifactorial genetic model. PLoS ONE 6: e18743 doi:10.1371/journal.pone.0018743.
23. ThakkinstianA, IngsathitA, ChaiprasertA, RattanasiriS, SangthawanP, et al. (2011) A simplified clinical prediction score of chronic kidney disease: a cross-sectional-survey study. BMC Nephrol 12: 45.
24. KwonKS, BangH, BombackAS, KohDH, YumJH, et al. (2012) A simple prediction score for kidney disease in the Korean population. Nephrology (Carlton) 17: 278–284.
25. ChienKL, LinHJ, LeeBC, HsuHC, LeeYT, et al. (2010) A prediction model for the risk of incident chronic kidney disease. Am J Med 123: 836–846.e2.
26. AndoM, YanagisawaN, AjisawaA, TsuchiyaK, NittaK (2011) A simple model for predicting incidence of chronic kidney disease in HIV-infected patients. Clin Exp Nephrol 15: 242–247.
27. JardineMJ, HataJ, WoodwardM, PerkovicV, NinomiyaT, et al. (2012) Prediction of kidney-related outcomes in patients with type 2 diabetes. Am J Kidney Dis E-pub ahead of print. doi:10.1053/j.ajkd.2012.1004.1025.
28. LeveyAS, BoschJP, LewisJB, GreeneT, RogersN, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461–470.
29. LeveyAS, StevensLA, SchmidCH, ZhangYL, CastroAF3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612.
30. FoxCS, GonaP, LarsonMG, SelhubJ, ToflerG, et al. (2010) A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 21: 2143–2149.
31. O'SeaghdhaCM, YangQ, WuH, HwangSJ, FoxCS (2012) Performance of a genetic risk score for CKD stage 3 in the general population. Am J Kidney Dis 59: 19–24.
32. O'SeaghdhaCM, LyassA, MassaroJM, MeigsJB, CoreshJ, et al. (2012) A risk score for chronic kidney disease in the general population. Am J Med 125: 270–277.
33. TangriN, StevensLA, GriffithJ, TighiouartH, DjurdjevO, et al. (2011) A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305: 1553–1559.
34. Hippisley-CoxJ, CouplandC (2010) Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores. BMC Fam Pract 11: 49.
35. KshirsagarAV, BangH, BombackAS, VupputuriS, ShohamDA, et al. (2008) A simple algorithm to predict incident kidney disease. Arch Intern Med 168: 2466–2473.
36. CollinsG, AltmanD (2012) Predicting the risk of chronic kidney disease in the UK: an evaluation of QKidney(R) scores using a primary care database. Br J Gen Pract 62: 243–250.
37. BangH, MazumdarM, KernLM, ShohamDA, AugustPA, et al. (2008) Validation and comparison of a novel screening guideline for kidney disease: KEEPing SCORED. Arch Intern Med 168: 432–435.
38. BangH, MazumdarM, NewmanG, BombackAS, BallantyneCM, et al. (2009) Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. Nephrol Dial Transplant 24: 2452–2457.
39. KeaneWF, ZhangZ, LylePA, CooperME, de ZeeuwD, et al. (2006) Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol 1: 761–767.
40. DesaiAS, TotoR, JarolimP, UnoH, EckardtKU, et al. (2011) Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 58: 717–728.
41. GotoM, KawamuraT, WakaiK, AndoM, EndohM, et al. (2009) Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm. Nephrol Dial Transplant 24: 1242–1247.
42. GotoM, WakaiK, KawamuraT, AndoM, EndohM, et al. (2009) A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant 24: 3068–3074.
43. WakaiK, KawamuraT, EndohM, KojimaM, TominoY, et al. (2006) A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 21: 2800–2808.
44. JohnsonES, ThorpML, PlattRW, SmithDH (2008) Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study. Am J Kidney Dis 52: 653–660.
45. LandrayMJ, EmbersonJR, BlackwellL, DasguptaT, ZakeriR, et al. (2010) Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 56: 1082–1094.
46. van DierenS, BeulensJW, KengneAP, PeelenLM, RuttenGE, et al. (2012) Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 98: 360–369.
47. HallanSI, RitzE, LydersenS, RomundstadS, KvenildK, et al. (2009) Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 20: 1069–1077.
48. HalbesmaN, JansenDF, HeymansMW, StolkRP, de JongPE, et al. (2011) Development and validation of a general population renal risk score. Clin J Am Soc Nephrol 6: 1731–1738.
49. AlssemaM, NewsonRS, BakkerSJ, StehouwerCD, HeymansMW, et al. (2012) One risk assessment tool for cardiovascular disease, type 2 diabetes, and chronic kidney disease. Diabetes Care 35: 741–748.
50. KentDM, JafarTH, HaywardRA, TighiouartH, LandaM, et al. (2007) Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18: 1959–1965.
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2012 Číslo 11
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- MUDr. Dana Vondráčková: Hepatopatie sú pri liečbe metamizolom väčším strašiakom ako agranulocytóza
- Vztah mezi statiny a rizikem vzniku nádorových onemocnění − metaanalýza
- Nech brouka žít… Ať žije astma!
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map
- Screening for Chronic Kidney Disease: Preventing Harm or Harming the Healthy?
- The Long-Term Health Consequences of Child Physical Abuse, Emotional Abuse, and Neglect: A Systematic Review and Meta-Analysis
- Screening and Rapid Molecular Diagnosis of Tuberculosis in Prisons in Russia and Eastern Europe: A Cost-Effectiveness Analysis